Top 20 ADC CDMOs in 2027: Who Can Actually Make Antibody Drug Conjugates

An antibody drug conjugate is three manufacturing problems fused into one product. An antibody must be grown and purified like any biologic. A cytotoxic payload and its linker must be synthesized under containment strict enough to protect workers. Then the two must be chemically joined and filled into sterile vials without losing potency or creating aggregates. Few contract manufacturers master all three, which is why capability, not size, should decide who ranks where.

Demand is rising fast. As of June 30, 2026, 23 ADCs had been approved worldwide, according to a landscape analysis by ChemExpress, a supplier that publishes this tracking. DataLookout counted 711 active ADC trials on ClinicalTrials.gov on August 20, 2026, including 106 in Phase 3. Hanson Wade’s Beacon database tracked 2,334 antibody-based drug conjugates in January 2026, with about 17% in clinical development. Every one of those programs needs a plan for GMP supply.

Anatomy of an ADC: Three Parts, Three Manufacturing Problems

An ADC has three parts: a targeting antibody, a chemical linker, and a cytotoxic payload. Each demands different expertise.

Two more points matter. Drug to antibody ratio, or DAR, controls efficacy and toxicity, so analytical characterization is a core service, not an add-on. And development differs from commercial supply: early projects need flexibility and small suites, while commercial supply needs validated scale, dual sourcing, and inspection history.

Biologics Scale Is Not ADC Capability

The biggest mistake in sourcing is treating a large biologics CDMO as an ADC CDMO. Antibody capacity is measured in thousands of liters, while conjugation suites are measured in hundreds. Lonza’s planned 1,200 L suites and Samsung’s 500 L ADC reactor are small compared with antibody bioreactors, because conjugation steps handle potent material at lower volumes. A company can hold enormous antibody capacity and still lack containment, payload chemistry, or conjugation experience.

Payload-linker supply is the second bottleneck. Complex linker-payloads require multistep synthesis under high containment, and capacity for them is scarce. Lonza’s June 2026 announcement framed its Visp expansion as a response to demand for highly complex payload-linkers. Sponsors that book conjugation slots without securing payload supply can still face delays.

Commercial experience is the third filter. Piramal’s batch count and Lonza’s commercial history show repeated execution, while newer entrants have shorter records. A 500 L reactor can support clinical programs well, yet commercial supply requires validated processes, inspection history, and dual sourcing.

Choosing a Model: Integrated, Specialist, or Multi-Vendor

Single-provider models reduce handoffs between sites, but they concentrate risk. Multi-vendor chains offer flexibility and dual sourcing but add technology transfer, comparability, and logistics work. For potent payloads, shipping intermediates between sites can also add regulatory complexity.

The Screening Matrix

Each company was checked against five layers: antibody production, payload and linker or HPAPI synthesis, conjugation, analytical development, and sterile fill finish. Revenue and general biologics scale were not used, because they do not prove ADC capability. A supplier of instruments or consumables is not an integrated CDMO. A 2026 analyst comparison from IntuitionLabs sorts the field into three tiers, and this article uses a similar logic: integrated commercial platforms, specialist bioconjugation CDMOs, and HPAPI or payload-linker specialists.

“Verify” means the capability was not confirmed in the sources reviewed, not that it is absent. Headquarters and site details should be confirmed on each company’s website.

Integrated ADC Platforms: Antibody Through Drug Product

1. Lonza: The Most Fully Documented End-to-End Chain

Lonza offers one of the most comprehensive documented ADC manufacturing chains in the source material, covering antibody manufacture, highly potent payload-linkers, conjugation, and drug product across its Visp and Stein facilities in Switzerland. The company has stated that it manufactures the majority of commercially available ADCs, although this remains a company claim. Its integrated model is particularly relevant to sponsors seeking to reduce the number of technology transfers between separate suppliers.

The company is also expanding its ADC infrastructure. In June 2026, Lonza announced additional payload-linker capacity at Visp planned for 2028. In October 2026, it announced three multiproduct bioconjugation suites of up to 1,200 liters for 2028, alongside 500-liter single-use capacity planned for 2027. It also announced ADC technology licensing agreements and an expanded collaboration with an undisclosed U.S. biopharma company.

For sponsors, the key issue is distinguishing announced capacity from capacity available today. Lonza has indicated that it is evaluating U.S. bioconjugation capabilities, which could eventually provide greater geographic flexibility. Before selecting the platform, sponsors should confirm the specific suite, production date, payload-transfer arrangements, available manufacturing slots, and whether planned expansions affect the timing of their clinical or commercial program.

2. Piramal Pharma Solutions: Bioconjugation Depth in Scotland

Piramal Pharma Solutions operates a dedicated bioconjugation facility in Grangemouth, Scotland, with FDA and MHRA accreditations. Its ADC-related capabilities include linker-payload services, conjugation, analytical support, and fill finish through its Lexington operations. This gives the company meaningful depth across several stages of ADC development, although antibody supply generally remains the customer’s responsibility and may require a separate biologics partner.

Piramal announced its 1,500th ADC batch on March 16, 2026, describing the milestone as covering clinical, commercial, and non-GMP batches. The company has also expanded its infrastructure through a £45 million investment that added two suites to its existing three. A separate $90 million U.S. investment announced in 2025 is expanding Lexington fill finish and Riverview capabilities, supporting its ADCelerate offering and broader manufacturing network.

Its combination of dedicated bioconjugation expertise and growing U.S. infrastructure can appeal to sponsors planning clinical or commercial programs. The main consideration is how antibody material will move into the process and how responsibilities are divided between sites. Sponsors should ask how many commercial batches were produced in the relevant suite, how antibody and payload shipments are qualified, and which facility would remain responsible for each manufacturing stage.

3. AGC Biologics: Antibody Production Within an Alliance

AGC Biologics is primarily a biologics CDMO, but the source material identifies its participation in the Proveo ADC alliance as part of its ADC-related offering. The alliance model suggests a pathway that can combine antibody production with downstream conjugation capabilities through partner organizations. For sponsors, this type of arrangement may reduce the need to coordinate every ADC manufacturing step independently.

Its documented role is more focused on biologics manufacturing than on independently operating a fully integrated ADC platform. The source material indicates that antibody production can be combined with conjugation, while payload-linker activities may be provided through partners. This structure can be useful when a sponsor already has a defined ADC molecule but needs coordinated manufacturing across biological and chemical components.

The important issue is contractual responsibility. Sponsors should determine which organization performs each stage, where conjugation actually occurs, who controls the payload-linker supply, and which party carries responsibility if a manufacturing step fails. Before committing, it is also important to understand technology-transfer requirements, quality agreements, release responsibilities, and how changes at one alliance partner could affect the overall development timeline.

4. WuXi Biologics and WuXi XDC: Scale With Geopolitical Exposure

WuXi’s ADC manufacturing model combines the biologics capabilities of WuXi Biologics with the bioconjugation and related services associated with WuXi XDC. According to the source material, much of the ADC capability sits within WuXi XDC, which became a separately listed company after raising approximately $520 million through a Hong Kong IPO in November 2023. WuXi Biologics provides the antibody manufacturing component.

The platform has been described alongside Lonza and Catalent as a large integrated ADC manufacturing option. WuXi XDC has also invested in international infrastructure, including a roughly 25,000-square-meter facility in Singapore according to the analyst comparison cited in the source. This geographic expansion can potentially give sponsors additional options for regional manufacturing and supply-chain planning.

The major consideration is geopolitical exposure rather than technical capability alone. U.S. policy discussions surrounding the BIOSECURE framework could affect how some sponsors assess Chinese-linked biotechnology suppliers, although the current policy position should be independently checked before making a decision. Sponsors should identify the contracting entity, map every manufacturing location, and establish contingency plans if trade restrictions, regulatory requirements, or supply-chain conditions change.

5. Catalent: Bioconjugation Under New Ownership

Catalent has bioconjugation and fill-finish capabilities and has been grouped with Lonza and WuXi XDC as a major integrated ADC platform. Its combination of drug substance and drug product capabilities can be relevant to sponsors seeking fewer manufacturing handoffs. The company has historically supported pharmaceutical development and manufacturing programs across multiple stages, although ADC scope needs to be evaluated at the individual facility level.

A major factor in evaluating Catalent is its ownership structure. Novo Holdings completed its acquisition of Catalent in December 2024, while several fill-finish sites were transferred to Novo Nordisk. These changes make it particularly important for sponsors to understand which facilities remain available to external customers and which operations are now connected to the broader Novo ecosystem.

Sponsors should therefore avoid evaluating Catalent solely on its historical global footprint. The relevant questions are which site will perform conjugation, where drug product will be manufactured, and whether the proposed facilities have capacity for the required development or commercial timeline. Buyers should also clarify how ownership changes affect third-party programs, scheduling priorities, confidentiality, and long-term manufacturing commitments.

6. Abzena: Engineering Plus Conjugation

Abzena is a specialist provider focused on antibody engineering, conjugation chemistry, linker-payload development, analytical services, and ADC process development. This combination makes it particularly relevant during the early stages of ADC development, when sponsors may still be optimizing the antibody construct, conjugation strategy, or payload-linker architecture. Its specialist model can provide continuity between molecular design and process development.

The company is particularly suitable for biotechnology companies that need technical support before an ADC reaches large-scale commercial manufacturing. A sponsor can potentially use Abzena for antibody engineering and conjugation-related development while building a manufacturing strategy for later clinical or commercial stages. Its capabilities are therefore more aligned with development and process design than with operating a complete high-volume commercial supply chain.

The major limitation is that Abzena does not provide the same large-scale commercial fill-finish infrastructure as the largest integrated CDMOs. Sponsors should plan the eventual handoff to another manufacturing organization well in advance. Important questions include how technology will be transferred, which analytical methods must be qualified by the receiving site, and whether Abzena’s process documentation is structured to support a later commercial manufacturing transition.

7. Ajinomoto Bio-Pharma Services: Bioconjugation With Containment

Ajinomoto Bio-Pharma Services provides biopharmaceutical development and manufacturing capabilities, including bioconjugation, API manufacturing, and GMP-related services. The source material places it among providers with specialized containment capabilities relevant to ADC work. This makes it potentially useful for programs involving highly potent materials that require controlled handling and specialized manufacturing environments.

The main consideration is understanding the exact scope available at each facility. ADC manufacturing can involve multiple specialized operations, including payload handling, linker chemistry, conjugation, purification, and drug-product processing. The presence of general bioconjugation or API capabilities does not automatically establish that every required ADC step is available under the same GMP framework or at the same location.

Sponsors should therefore obtain site-specific documentation before treating Ajinomoto as an integrated ADC partner. Questions should cover the facility performing conjugation, containment levels, payload-handling capabilities, antibody supply arrangements, analytical testing, and GMP experience with comparable molecules. Clear site mapping is particularly important when several locations or partner organizations are involved in the proposed manufacturing chain.

8. Sterling Pharma Solutions: Chemistry-Led HPAPI

Sterling Pharma Solutions is a chemistry-led CDMO with capabilities in highly potent active pharmaceutical ingredients, linker-payload chemistry, and process development. Its position makes it relevant to ADC sponsors that need specialized chemistry support, particularly during development of potent intermediates. The company’s role is more naturally aligned with chemical manufacturing than with a fully integrated antibody-to-drug-product platform.

Its ADC relevance lies in the ability to support complex chemistry and highly potent materials. Such capabilities can be important because ADC payloads often require specialized containment, process controls, analytical methods, and handling procedures. For sponsors developing new payload-linker combinations, a chemistry-focused CDMO can provide an important manufacturing step even when another organization performs antibody production and final conjugation.

The key question is whether conjugation is performed directly by Sterling or coordinated through external partners. Sponsors should avoid assuming that payload-linker production automatically includes ADC conjugation. Before selection, they should confirm the largest payload batch successfully produced, containment requirements, analytical support, GMP history, and the process for transferring the resulting material to the next manufacturing partner.

9. Samsung Biologics: A Newer Entrant With Antibody Scale

Samsung Biologics entered ADC manufacturing in 2025 with a dedicated facility in Songdo featuring a 500-liter reactor and purification capabilities. The company has also extended work with LigaChem Biosciences while maintaining its established strength in large-scale antibody manufacturing. This combination gives Samsung a potentially attractive starting point for sponsors that value biologics scale alongside newer ADC capabilities.

Its ADC manufacturing experience is more recent than that of established specialists such as Lonza and Piramal. The source material describes the facility as a segregated suite rather than a large commercial production line, and payload-linker sourcing is not documented in the reviewed information. Samsung has also acquired a U.S. site from GSK in Rockville, Maryland, which could become relevant to sponsors seeking North American manufacturing options.

The main issue for sponsors is the depth of demonstrated ADC manufacturing experience. Before selecting Samsung for a major program, buyers should ask how many GMP ADC batches the relevant suite has produced, which molecules have reached commercial manufacturing, and who supplies the payload-linker. The answers will help distinguish the company’s established antibody manufacturing strength from its newer ADC-specific manufacturing capabilities.

10. CARBOGEN AMCIS: Swiss Potent Compound Synthesis

CARBOGEN AMCIS is a Swiss specialist with capabilities in potent compound synthesis and linker-payload chemistry. Its expertise makes it relevant to ADC sponsors that require highly potent intermediates or specialized chemical manufacturing before conjugation. The company can therefore fit into a distributed ADC supply chain where one provider handles payload chemistry while another performs antibody production and bioconjugation.

Its strongest potential contribution is the production of complex and highly potent chemical components. ADC payloads can require specialized containment and process controls because of their potency, and experienced HPAPI facilities can reduce some of the operational challenges associated with handling these materials. However, payload-linker manufacturing and ADC conjugation should be treated as separate capabilities unless the provider confirms that both are performed at the relevant site.

Sponsors should therefore establish precisely where the chemical work ends and whether CARBOGEN AMCIS performs any downstream conjugation. The important technical questions include containment limits, maximum batch size, analytical capabilities, regulatory inspection history, and experience with the specific type of payload chemistry required. Site-specific verification is essential before assigning a critical manufacturing step.

11. Cerbios-Pharma: Potent Compounds and Bioconjugation

Cerbios-Pharma, based in Ticino, Switzerland, is associated with potent compounds and bioconjugation capabilities. Its positioning makes it potentially relevant to ADC programs requiring specialized handling of potent materials. However, the source material specifically notes that its ADC scope was not fully verified, so sponsors should treat the company as a potential partner rather than assuming it provides every stage of an integrated ADC process.

The company may be particularly useful where the manufacturing requirement involves highly potent compounds or specialized bioconjugation activities. For ADC programs, that could include selected development or manufacturing stages rather than the complete antibody-to-drug-product chain. Its geographic location may also appeal to European sponsors seeking to maintain several critical manufacturing activities within a relatively concentrated regional network.

Because the documented ADC scope remains incomplete, verification should be a central part of the selection process. Sponsors should request a current capability statement, facility list, GMP certifications, and specific examples of ADC programs that reached GMP manufacturing. It is also important to identify which site would handle the work, what containment level applies, and whether the provider can support the sponsor’s intended clinical or commercial scale.

12. Recipharm: Sterile and High-Potency Manufacturing

Recipharm is a European CDMO with capabilities spanning sterile manufacturing and high-potency pharmaceutical production. Its potential relevance to ADC programs is more closely associated with drug-product manufacturing than with the complete conjugation chain. This makes it a possible partner for sponsors that already have antibody, payload, and conjugation arrangements but need specialized downstream manufacturing support.

Sterile and potent drug-product manufacturing can be particularly important for ADCs because the final product must meet strict quality, sterility, containment, and release requirements. Recipharm’s broader pharmaceutical manufacturing infrastructure may therefore provide useful support for selected ADC programs. However, the source material does not establish the full scope or scale of its dedicated ADC experience, so this should not be assumed from its general sterile manufacturing capabilities.

Sponsors considering Recipharm should request examples of ADC or comparable high-potency drug products that have actually been manufactured at the proposed site. Questions should cover containment, aseptic processing, batch size, lyophilization if required, analytical release, regulatory inspections, and experience handling potent oncology products. These details will determine whether the site is suitable for the specific drug-product stage.

13. Merck KGaA, MilliporeSigma: Supplier Technology Versus CDMO Work

Merck KGaA, including its MilliporeSigma operations, occupies a different position from a conventional integrated ADC CDMO. The company supplies process technologies, analytical solutions, reagents, filters, and other materials used in ADC development and manufacturing, while also operating contract-service capabilities through parts of its organization. This distinction is important when evaluating it as an ADC manufacturing partner.

For sponsors, Merck’s value may lie in supplying critical technologies and materials that enable ADC development rather than performing every manufacturing step itself. Its products can support laboratory development, process optimization, filtration, analytics, and manufacturing operations. However, the existence of a relevant product or technology does not necessarily mean that Merck will directly manufacture the sponsor’s ADC drug substance or drug product.

The commercial proposal therefore needs careful interpretation. Sponsors should determine whether they are purchasing process materials and equipment or contracting for a manufacturing service. The same distinction applies to responsibility for GMP production, batch release, technology transfer, and quality oversight. Clarifying this early prevents supplier relationships from being mistakenly treated as equivalent to an integrated CDMO partnership.

14. Thermo Fisher Scientific, Patheon: Sterile Capacity at Scale

Thermo Fisher Scientific provides pharmaceutical development and manufacturing services through Patheon, including sterile drug-product manufacturing capabilities. Its scale and broad pharmaceutical infrastructure can make it relevant to ADC sponsors seeking downstream manufacturing support. However, the source material emphasizes that ADC capability depends on the individual site rather than being uniformly available throughout the network.

For ADC programs, the most relevant requirements may include sterile fill finish, handling of potent oncology products, analytical support, and appropriate containment. A sponsor may therefore use a Patheon facility after antibody production and conjugation have been completed elsewhere. This can be useful when the manufacturing strategy intentionally separates drug-substance and drug-product operations across specialized sites.

Site selection is critical because the capabilities of one Patheon facility cannot automatically be assumed to apply to another. Sponsors should request the exact proposed manufacturing location, containment level, inspection history, batch-size range, and evidence of prior commercial ADC or comparable high-potency fill-finish work. The contract should also clearly define technology-transfer responsibilities and release testing.

15. FUJIFILM Biotechnologies: Antibody Manufacturing Muscle

FUJIFILM Biotechnologies, formerly FUJIFILM Diosynth Biotechnologies, is a major biologics manufacturer with substantial antibody production capabilities. Its scale makes it a strong candidate when an ADC sponsor primarily needs reliable antibody drug-substance manufacturing. However, the source material does not establish a fully integrated ADC chain, so conjugation and fill finish should be evaluated separately.

For sponsors, strong antibody manufacturing capacity can provide an important foundation for ADC development. Consistent antibody quality, scalable production, process control, and reliable supply are critical before the material enters downstream conjugation. FUJIFILM’s broader biologics infrastructure can therefore be valuable even when the company is not responsible for payload chemistry or final ADC drug product.

The key question is how the antibody supply chain connects to the remaining ADC manufacturing steps. Sponsors should identify which partner performs conjugation, where payload-linker material is manufactured, and which organization handles final fill finish. A well-defined technology-transfer and logistics plan is especially important because antibody quality and consistency must be maintained across the transition into the conjugation process.

16. Axplora: HPAPI and Payload-Linker Chemistry

Axplora, formed through the combination of Novasep and Farmabios, provides specialized chemical manufacturing capabilities including HPAPI synthesis and complex chemistry. Its position in the ADC ecosystem is primarily connected to potent payload and linker-payload work rather than complete antibody-to-drug-product manufacturing. This makes it useful as a specialist component within a broader outsourced supply chain.

The company’s chemistry capabilities can support sponsors developing potent ADC payloads that require specialized containment and process development. Such work may include manufacturing advanced intermediates, scaling complex chemical reactions, and producing highly potent materials for subsequent conjugation. However, the source material does not document conjugation or fill finish as part of its core ADC offering.

Sponsors should therefore plan Axplora as a chemistry partner unless a specific site confirms additional ADC services. An important consideration is the handoff from chemical manufacturing to the conjugation facility. Buyers should clarify shipping requirements, packaging and containment, analytical release, batch documentation, stability expectations, and responsibilities for investigating deviations during transfer.

17. Oncotec Pharma Produktion: Cytotoxic Fill Finish

Oncotec Pharma Produktion specializes in aseptic manufacturing of cytotoxic oncology products in Germany, making it a potentially relevant downstream partner for ADC drug product. Its focus on potent oncology medicines is particularly relevant because ADCs combine biologic components with highly active cytotoxic payloads. The company therefore occupies a specialized position within the final stages of an ADC manufacturing chain.

Its potential role is primarily associated with fill finish rather than antibody production or payload-linker chemistry. The source material identifies it as a plausible partner for ADC drug product, but specific experience with ADC products, including lyophilization, requires verification. For sponsors, this distinction is important because general cytotoxic manufacturing experience does not automatically demonstrate the ability to process every ADC formulation.

Before selection, sponsors should request evidence of prior ADC drug-product manufacturing and determine whether the relevant facility supports the required formulation and filling process. Questions should cover lyophilization, containment, cross-contamination controls, aseptic processing, batch sizes, inspection history, and release testing. These factors will determine whether Oncotec can support clinical and eventual commercial requirements.

18. SK pharmteco: A Platform of Several Units

SK pharmteco operates as a CDMO platform incorporating multiple manufacturing units across Europe and the United States. Its relevance to ADC programs is associated primarily with potent API and linker chemistry. Because the organization spans several facilities and technical capabilities, it can potentially contribute to specialized portions of an ADC manufacturing chain rather than acting as a single-site antibody-to-drug-product provider.

The source material does not fully verify its current ADC-specific scope, so sponsors should avoid treating the platform as an established integrated ADC manufacturer without further documentation. Its chemistry capabilities may nonetheless make it a candidate for payload or linker-related work, particularly when a sponsor needs highly potent material manufactured under controlled conditions.

The most important diligence step is identifying the exact operating unit responsible for the project. Sponsors should request site-specific capabilities, GMP status, containment limits, batch sizes, regulatory inspection history, and previous experience with comparable potent molecules. They should also determine how material moves between SK pharmteco units and external conjugation or fill-finish partners if the project requires additional manufacturing stages.

19. Bora Biologics: Antibody Supply Candidate

Bora Biologics is a Taiwan-based CDMO focused on antibody and biologics manufacturing. Its primary relevance to ADC programs is therefore the production and supply of antibody material rather than a clearly documented integrated conjugation platform. For sponsors developing an ADC, this can still represent an important manufacturing role because reliable antibody supply is a prerequisite for downstream conjugation.

The company may be considered when a sponsor wants to separate antibody production from payload chemistry and conjugation. This approach allows each manufacturing partner to specialize in a defined part of the process and can provide flexibility when the sponsor already has relationships with specialized ADC or HPAPI providers. However, dedicated bioconjugation capabilities were not confirmed in the source material.

Sponsors should therefore treat Bora Biologics primarily as an antibody-supply candidate until additional documentation demonstrates broader ADC capabilities. Important questions include whether it operates a dedicated conjugation suite, whether any ADC batches have been produced under GMP, what scales are available, and how antibody material is packaged and transferred to the downstream conjugation partner.

20. Shilpa Biologicals: A Claimed Integrated Infrastructure

Shilpa Biologicals is an Indian biologics company that has described an integrated infrastructure for ADC-related manufacturing. Its positioning is therefore potentially broader than a conventional antibody-only CDMO, particularly for sponsors looking for an India-based manufacturing option. However, the source material emphasizes that commercial readiness and regulatory status require independent confirmation before treating the platform as a proven integrated ADC supplier.

For an ADC sponsor, an integrated infrastructure claim is only meaningful when each manufacturing stage can be independently demonstrated. This includes antibody production, payload and linker handling, conjugation, purification, analytical testing, and final drug-product manufacturing where applicable. The regulatory status of each relevant facility and the ability to support clinical or commercial GMP production are equally important.

Sponsors should conduct detailed technical and regulatory diligence before committing a program. Audit reports, inspection histories, GMP documentation, facility capabilities, containment controls, and evidence of prior ADC manufacturing should all be reviewed. The key questions are which regulatory agencies have inspected the relevant ADC suites, which steps are actually performed in-house, and what evidence supports commercial readiness.

Due-Diligence Checklist

Outsourcing Risks to Plan For

Technology transfer is the main hazard, since small differences in conjugation conditions change DAR distribution. Highly potent compounds raise cross-contamination and exposure risk. Supply chains are fragile because payloads, linkers, antibodies, and vials often come from different sites. Capacity is tightening as sponsors compete for the same suites, and reserving a slot early is often the only way to protect a launch date. Intellectual property protection matters when multiple vendors see parts of a process. Finally, announced expansions are not available capacity, so contract dates should rely on commissioned facilities and on written commissioning schedules.

Where ADC Manufacturing Goes Next

Integrated capability, not general biologics scale, separates a true ADC partner from a candidate. Lonza, Piramal, WuXi XDC, and Samsung have documented ADC chains in the sources reviewed, while many others need individual confirmation. The right choice depends on stage, payload, scale, and risk tolerance.

Next-generation ADCs, novel payloads, and bispecific formats will stretch containment and analytics further. Select on technical fit, quality systems, and regulatory readiness, and treat announced capacity as a plan, not a guarantee. Ask for audit reports, visit the exact suite, and write capacity reservations, technology transfer terms, and supply continuity obligations into the quality and commercial agreements before the first batch is scheduled. A shortlist built on verified capability will save months that a mismatched partner would cost.

ADC Manufacturing: Common Questions

Q: What is an ADC CDMO?

A: A contract development and manufacturing organization that makes antibody drug conjugates or key parts, such as antibodies, payload-linkers, conjugation, or sterile drug product.

Q: Which companies manufacture antibody drug conjugates?

A: Lonza, Piramal Pharma Solutions, WuXi XDC, and Samsung Biologics have documented ADC services, and several others, including Abzena and Catalent, offer parts of the chain.

Q: What services do ADC CDMOs provide?

A: Process development, payload-linker synthesis, antibody production, conjugation, analytics, GMP manufacturing, and fill finish.

Q: Why do ADCs require specialized manufacturing?

A: They combine biologics, small molecule chemistry, and highly potent compounds that require containment and tight control of drug to antibody ratio.

Q: What is bioconjugation in ADC production?

A: The chemical step that attaches the linker-payload to the antibody, controlling how many payload molecules each antibody carries.

Q: What is HPAPI manufacturing?

A: Production of highly potent active pharmaceutical ingredients, handled in contained facilities because tiny amounts can harm operators.

Q: What is the difference between a biologics CDMO and an ADC CDMO?

A: A biologics CDMO makes antibodies and proteins. An ADC CDMO also handles potent chemistry, conjugation, and specialized analytics.

Q: How should pharmaceutical companies select an ADC manufacturing partner?

A: Compare containment, conjugation experience, analytics, inspection history, and capacity, and confirm each claim with documents for the exact site.